Preferred Label : CDK4/6 Inhibitor BPI-16350;
NCIt definition : An orally bioavailable inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and
6 (CDK6), with potential antineoplastic activity. Upon administration, CDK4/6 inhibitor
BPI-16350 selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of
retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase
transition and leads to cell cycle arrest. This suppresses DNA replication and decreases
tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated
in many tumor cell types and play a key role in the regulation of both cell cycle
progression from the G1-phase into the S-phase and tumor cell proliferation.;
Molecule name : BPI 16350; BPI-16350;
NCI Metathesaurus CUI : CL937081;
Origin ID : C157481;
UMLS CUI : C4763649;
Semantic type(s)
- concept_is_in_subset
- has_target
